Connection of HCMV load levels and clinical severity of HCMV manifestation. (A) The incidence of csCMVi onset among patients with csCMVi was monitored from day 0 to day +360. CsCMVi events were reported at the end of each month based on their diagnosis date. (B) Peak HCMV DNA copies per milliliter measured by polymerase chain reaction until day +365 in patients who underwent alloSCT, serving as control for HCMV (controllers, blue) or those with csCMVi (brown). Patients with csCMVi were further subdivided into patients without (gray) or with Rf/EOD (red). ∗P < .05, ∗∗∗P < .001 using Mann-Whitney U test.